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 Diffuse large B-cell lymphoma
 Thrombocytopenia
a b s t r a c t
Hemophagocytic syndrome (HPS) is an extremely rare and life-threatening abnormality,
and the cases secondary to B cell lymphoma are rare. We report a case of relapsed
diffuse large B-cell lymphoma initially presenting with hemophagocytic syndrome. The
patient developed multiple erythematous macules and progressive thrombocytopenia
during the treatment, and died two weeks after admission. The HPS presented as an
initial manifestation of the relapsed diffuse B-cell lymphoma and the maculea that
appeared during the treatment might be a strong predictor of unfavorable outcome.
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Hemophagocytic syndrome (HPS) is a rare disorder character-
ized by persistent fever without clear cause, hepatosplenome-
galy, cytopenia, deranged liver function, hypertriglyceridemia,
hyperferritinemia and hemophagocytosis in bone marrow [1].
Acquired HPS in adults is associated with various causes
including infections, connective tissue diseases, and malig-
nancies, especially non-Hodgkin's lymphoma [2]. In contrast
to T or NK/T cell lymphoma, B-cell lymphoma associated
with HPS is extremely rare [3, 4]. And hemophagocytic
syndrome secondary to the relapsed B-cell lymphoma
has never been reported before. We herein reported an
unusual and life-threatening presentation of hemophagocytic
syndrome in a patient with relapsed diffuse large B-cell
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An 81-year-old man was admitted to our hospital presenting
with a 4-week history of fever of exceeding 38 8C and
weakness of the lower limbs. Two years before this episode,
he had developed diffuse large B-cell lymphoma of
the tongue, and had been successfully treated with wide
excision of the lesion followed by chemotherapy and radio-
therapy. On examination, the abdomen showed hepatosple-
nomegaly and there was no superficial lymphadenopathy.
Laboratory examination showed normal white blood cell,
thrombocytopenia with a platelet count of 77  109/L and
hemoglobin level of 77 g/L. Negative results of coagulation
testing including activated partial thromboplastin time (aPTT),
prothrombin time (PT), antithrombin III (AT) activity, fibrino-
gen concentration, fibrin–fibrinogen degradation productdical College, Huazhong University of Science and Technology,
x: +86 27 85755457.
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Fig. 2 – Widespread erythematous macules on the trunk
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nosis of disseminated intravascular coagulation (DIC). He was
also noted to have elevated levels of aspartate aminotransfer-
ase (105 U/L), alanine aminotransferase (112 U/L), lactate
dehydrogenase (1257 U/L) and ferritin (10 414.56 pmol/L). Ser-
ological tests for virus infection including Epstein–Barr virus,
cytomegalovirus, human immunodeficiency virus, hepatitis
B and C virus were all negative. The bone marrow aspiration
revealed macrophages distributed throughout the bone mar-
row. Computed tomographic (CT) scan revealed lesions of
lungs suggesting localization of lymphoma and magnetic
resonance imaging (MRI) showed multiple epidural mass
lesions at T4, L2 and L4 with compression of the spinal cord
(Fig. 1). The result of CT-guided percutaneous lung biopsy
was consistent with diffuse large B cell lymphoma. These
findings together fulfilled the HLH-2004 criteria (fever, spleno-
megaly, cytopenias, hyperferritinaemia and hemophagocyto-
sis in the bone marrow). Thus, a diagnosis of
hemophagocytic syndrome secondary to the relapsed diffuse
large B-cell lymphoma was finally made. Immediately after
initiation of treatment with a 1000-mg methylprednisolone
pulse for 3 days and intravenous immunoglobulin (0.4 g/kg/
day for 5 days), the fever stopped and the platelet count
returned to 101  109/L. However, on the 3rd day of the
treatment, the patient suddenly developed various-sized,
tender and slightly infiltrated erythematous macules on the
face and trunk (Fig. 2). A careful review of the patient's
medication lists ruled out the possibility of drug-induced
rash. Meanwhile, the platelet count decreased rapidly to
59  109/L on the 5th day of treatment and even to 7  109/L
on the 9th day of treatment. In addition, the hemoglobin level
also decreased to 57 g/L on the 5th day of treatment. During
this period, the patient had been dependent on platelet
transfusions, which became gradually more frequent. He got
worse around the 12th day after admission. The family
decided to discontinue further therapies, and the patient diedFig. 1 – (A–C) CT and MRI images of the patient at the
diagnosis of HPS. CT image (A) showed a metastatic lesion
(arrow) in the right lung on mediastinal window.
T2-weighted images (B–C) showed epidural mass lesion
(arrow) at T4 level with compression of the spinal cord
(asterisk)of circulatory and respiratory distresses due to HPS about two
weeks after admission.
Discussion
The clinical course of HPS may be fulminant with rapid
progression of symptoms, and the disease is usually fatal
without treatment. The clinical features, proper treatment,
and prognostic factors of HPS remain ill-defined because of
its rarity, difficulty in diagnosis, and the poor general
condition of the patient at the time of diagnosis [5–7]. The
Histiocyte Society has established the clinicopathologic
criteria for the diagnosis of HPS, which is defined by the
presence of at least 5 of the following 8 criteria, including
fever, splenomegaly, cytopenia (affecting 2 cell lines),
hypertriglyceridemia, hemophagocytosis in the bone mar-
row, low or absent NK cell cytotoxicity, hyperferritinemia,
and elevated soluble CD25 [8]. However, initial clinical
diagnosis is difficult since not all patients meet all of these
diagnostic criteria and many patients do so only in the late
course of their disease. Early diagnosis and treatment often
are essential for survival. In this case, the patient initially
presented with only fever and weakness of lower limbs
which was quite inconspicuous and easily misdiagnosed.
There may also be a long prodromal period of non-specific
illness before development of the complete syndrome. Since
acquired HPS is usually associated with lymphoma, in those
patients who present with manifestation of HPS, the suspi-
cion of tumor regression is often crucial.
Cutaneous manifestations in HPS are relatively uncom-
mon and detailed descriptions of skin lesions and their
histopathologic findings have rarely been reported. It can
accompany underlying hemophagocytic syndrome in the
form of purpuric, macular, papular, erythrodermic, or mor-
billiform eruptions [9–11]. Right now it is considered that
the pathophysiology of its cutaneous manifestations is
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The latter is associated with a generalized immune activa-
tion with release of proinflammatory cytokines, which can
cause the vicious circle of inflammatory ‘‘cytokine storm’’ of
infiltrated organ systems, including skin [12–14]. Thus, the
clinical cutaneous presentation in HPS may be an important
sign of the judgment of severity, effect of treatment, and
prognosis of the disease. The reappearance of cutaneous
manifestations in a patient may herald a recurrence of HPS
[15]. In our case, the fever stopped during the first few days
and the platelet count even returned to the normal range.
However, the patient immediately developed widespread
macules accompanied with the following progressive throm-
bocytopenia and paralysis of the lower limbs, and failed to
receive further chemotherapy. The macules that appeared
during the therapy was quite rare and might serve as
a strong predictor of unfavorable outcome.
In summary, hemophagocytic syndrome secondary to
the relapse diffuse B cell lymphoma is rare and has
a dismal prognosis with a quick disease progression. The
cutaneous presentation in the clinical course might be
a strong predictor of unfavorable outcome.
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